KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Income from Continuing Operations: 2018-2025

Historic Income from Continuing Operations for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to $9.5 million.

  • Adaptive Biotechnologies' Income from Continuing Operations rose 129.74% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 59.25%. This contributed to the annual value of -$159.6 million for FY2024, which is 29.16% up from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Income from Continuing Operations is $9.5 million, which was up 137.30% from -$25.6 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Income from Continuing Operations' 5-year high stood at $9.5 million during Q3 2025, with a 5-year trough of -$69.5 million in Q4 2023.
  • For the 3-year period, Adaptive Biotechnologies' Income from Continuing Operations averaged around -$39.2 million, with its median value being -$46.2 million (2024).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first slumped by 72.94% in 2023, then surged by 129.74% in 2025.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Income from Continuing Operations stood at -$61.4 million in 2021, then soared by 34.53% to -$40.2 million in 2022, then slumped by 72.94% to -$69.5 million in 2023, then surged by 51.46% to -$33.7 million in 2024, then skyrocketed by 129.74% to $9.5 million in 2025.
  • Its Income from Continuing Operations was $9.5 million in Q3 2025, compared to -$25.6 million in Q2 2025 and -$29.8 million in Q1 2025.